Eric D Peterson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4988427/publications.pdf

Version: 2024-02-01

397 papers

21,187 citations

69 h-index 126 g-index

404 all docs

404 docs citations

404 times ranked 23205 citing authors

#	Article	IF	CITATIONS
1	Temporal Trends in Post Myocardial Infarction Heart Failure and Outcomes Among Older Adults. Journal of Cardiac Failure, 2022, 28, 531-539.	0.7	11
2	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. European Journal of Heart Failure, 2022, 24, 169-180.	2.9	23
3	Achieving More Rapid Door-to-Needle Times and Improved Outcomes in Acute Ischemic Stroke in a Nationwide Quality Improvement Intervention. Stroke, 2022, 53, 1328-1338.	1.0	16
4	Risk-Adjusted, 30-Day Home Time After Transcatheter Aortic Valve Replacement as a Hospital-Level Performance Metric. Journal of the American College of Cardiology, 2022, 79, 132-144.	1.2	5
5	Association of Recent Use of Non–Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase. JAMA - Journal of the American Medical Association, 2022, 327, 760.	3.8	28
6	Evaluation of Evidence-Based Dual Antiplatelet Therapy for Secondary Prevention in US Patients With Acute Ischemic Stroke. JAMA Internal Medicine, 2022, 182, 559.	2.6	6
7	Effectiveness of Telemedicine Visits in Reducing 30â€Day Readmissions Among Patients With Heart Failure During the COVIDâ€19 Pandemic. Journal of the American Heart Association, 2022, 11, e023935.	1.6	29
8	Trends of blood pressure control in the U.S. during the COVID-19 pandemic. American Heart Journal, 2022, 247, 15-23.	1.2	40
9	Guidelines for Cardiovascular Risk Reduction in Patients With Type 2ÂDiabetes. Journal of the American College of Cardiology, 2022, 79, 1849-1857.	1.2	34
10	Validation of the WATCHâ€DM and TRSâ€HF _{DM} Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. Journal of the American Heart Association, 2022, 11, .	1.6	10
11	Time to benefit and harm of intensive blood pressure treatment: insights from SPRINT. European Heart Journal Quality of Care & Dutcomes, 2021, 7, e1-e2.	1.8	7
12	Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization. American Journal of Cardiology, 2021, 138, 26-32.	0.7	6
13	Association between intensive care unit utilization for patients with non–ST-segment elevation myocardial infarction and patient experience. American Heart Journal, 2021, 231, 32-35.	1.2	O
14	Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events?. American Journal of Cardiology, 2021, 142, 83-90.	0.7	0
15	Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease. American Heart Journal, 2021, 231, 36-44.	1.2	9
16	Generating evidence for therapeutic effects: the need for well-conducted randomized trials. Journal of Clinical Investigation, 2021, 131, .	3.9	6
17	Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Associated Willingness to Consider and Use Prevention Therapy. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006548.	0.9	20
18	Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage. JAMA Network Open, 2021, 4, e2037438.	2.8	21

#	Article	IF	CITATIONS
19	Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). American Journal of Cardiovascular Drugs, 2021, 21, 553-561.	1.0	5
20	The incremental value of angiographic features for predicting recurrent cardiovascular events: Insights from the Duke Databank for Cardiovascular Disease. Atherosclerosis, 2021, 321, 1-7.	0.4	1
21	Variation in Antithrombotic Therapy and Clinical Outcomes in Patients With Preexisting Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2021, 14, e009963.	1.4	7
22	Electronic Health Record Integration of Predictive Analytics to Select High-Risk Stable Patients With Non–ST-Segment–Elevation Myocardial Infarction for Intensive Care Unit Admission. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007602.	0.9	4
23	Prospective evaluation of lipid management following acute coronary syndrome in <scp>nonâ€Western</scp> countries. Clinical Cardiology, 2021, 44, 955-962.	0.7	5
24	Sex disparities in patients with symptomatic severe aortic stenosis. American Heart Journal, 2021, 237, 116-126.	1,2	16
25	The impact of race and ethnicity on outcomes in 19,584 adults hospitalized with COVID-19. PLoS ONE, 2021, 16, e0254809.	1.1	19
26	Sequential Evolution of Quality Assessment for Aortic Valvular Heart Interventions. Circulation, 2021, 144, 195-198.	1.6	3
27	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. JAMA Network Open, 2021, 4, e2117963.	2.8	5
28	Lipoprotein(a) Testing Patterns in a Large Health System. American Journal of Cardiology, 2021, 153, 43-50.	0.7	8
29	Association Between Patient Survival and Clinician Variability in Treatment Rates for Aortic Valve Stenosis. Journal of the American Heart Association, 2021, 10, e020490.	1.6	8
30	Perceived Versus Actual Risks of 30-Day Readmission in Patients With Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006586.	0.9	3
31	Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure. Stroke, 2021, 52, e777-e781.	1.0	2
32	Telehealth and 30-Day Readmissions Among Heart Failure Patients During the COVID-19 Pandemic. Innovation in Aging, 2021, 5, 465-466.	0.0	0
33	Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding. European Stroke Journal, 2020, 5, 47-55.	2.7	11
34	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal, 2020, 220, 145-154.	1,2	3
35	A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2020, 96, E102-E109.	0.7	10
36	The Accuracy of Cardiovascular Pooled Cohort Risk Estimates in U.S. Older Adults. Journal of General Internal Medicine, 2020, 35, 1701-1708.	1.3	31

#	Article	IF	Citations
37	Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. American Heart Journal, 2020, 219, 21-30.	1.2	8
38	Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications. JAMA Cardiology, 2020, 5, 38.	3.0	6
39	Racial Differences in Elevated Câ€Reactive Protein Among US Older Adults. Journal of the American Geriatrics Society, 2020, 68, 362-369.	1.3	18
40	Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. American Heart Journal, 2020, 219, 47-57.	1.2	45
41	Translating the Secondary Prevention Therapeutic Boom Into Action. JAMA Cardiology, 2020, 5, 215.	3.0	1
42	Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. American Heart Journal, 2020, 220, 82-88.	1.2	3
43	Effects of Virtual Exercise Rehabilitation In-Home Therapy Compared with Traditional Care After Total Knee Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2020, 102, 101-109.	1.4	131
44	Gerotechnology for Older Adults With Cardiovascular Diseases. Journal of the American College of Cardiology, 2020, 76, 2650-2670.	1.2	66
45	Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults. Journal of the American College of Cardiology, 2020, 76, 653-664.	1.2	39
46	China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial. American Heart Journal, 2020, 227, 47-55.	1.2	11
47	Timeâ€Dependent Cardiovascular Treatment Benefit Model for Lipid‣owering Therapies. Journal of the American Heart Association, 2020, 9, e016506.	1.6	8
48	Cardiovascular Biomarkers and Imaging in Older Adults. Journal of the American College of Cardiology, 2020, 76, 1577-1594.	1.2	21
49	Representation of Older Adults in Cardiovascular Disease Trials Since the Inclusion Across the Lifespan Policy. JAMA Internal Medicine, 2020, 180, 1531.	2.6	23
50	Prevalence and Management of Adult Obesity in a Large U.S. Academic Health System. American Journal of Preventive Medicine, 2020, 58, 817-824.	1.6	4
51	Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. Circulation: Cardiovascular Interventions, 2020, 13, e008274.	1.4	1
52	Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. European Heart Journal Quality of Care & Dical Outcomes, 2020, 6, 263-272.	1.8	16
53	Deprescribing Antihypertensive Medications for Patients Aged 80 Years or Older. JAMA - Journal of the American Medical Association, 2020, 323, 2024.	3.8	3
54	Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006182.	0.9	5

#	Article	IF	Citations
55	The Project Baseline Health Study: a step towards a broader mission to map human health. Npj Digital Medicine, 2020, 3, 84.	5 . 7	38
56	Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill. JAMA Cardiology, 2020, 5, 532.	3.0	8
57	Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. Thrombosis Research, 2020, 195, 128-135.	0.8	3
58	Racial Differences in Long-Term Cardiovascular Outcomes. JACC: Cardiovascular Interventions, 2020, 13, 1596-1598.	1.1	9
59	Efficacy and Safety of Intensive Blood Pressure Therapy Using Restricted Mean Survival Time—Insights from the SPRINT Trial. American Journal of Medicine, 2020, 133, e369-e370.	0.6	6
60	Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006019.	0.9	7
61	Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart, 2020, 106, 358-364.	1.2	16
62	Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). American Heart Journal, 2020, 226, 85-93.	1.2	13
63	Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry. American Heart Journal, 2020, 225, 88-96.	1.2	8
64	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). American Journal of Cardiology, 2020, 125, 1655-1660.	0.7	7
65	Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits. American Heart Journal, 2020, 224, 47-53.	1.2	44
66	Racial Differences in the Use of Aortic Valve Replacement for Treatment of Symptomatic Severe Aortic Valve Stenosis in the Transcatheter Aortic Valve Replacement Era. Journal of the American Heart Association, 2020, 9, e015879.	1.6	32
67	B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. Heart, 2019, 105, heartjnl-2018-313642.	1.2	22
68	The Association Between Lowâ€Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular Disease in Older Adults: Results From the National Institutes of Health Pooled Cohorts. Journal of the American Geriatrics Society, 2019, 67, 2560-2567.	1.3	26
69	The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice. Journal of Clinical Lipidology, 2019, 13, 725-734.	0.6	21
70	Sex Differences in the Use of Statins in Community Practice. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005562.	0.9	155
71	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke. JAMA Neurology, 2019, 76, 1192.	4.5	70
72	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiology, 2019, 4, 756.	3.0	10

#	Article	IF	CITATIONS
73	Representativeness of a HeartÂFailure Trial by Race and Sex. JACC: Heart Failure, 2019, 7, 980-992.	1.9	30
74	Associations between \hat{l}^2 -blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. American Heart Journal, 2019, 218, 92-99.	1.2	4
75	Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs. Thrombosis Research, 2019, 182, 159-166.	0.8	48
76	Opportunities for improving use of evidenceâ€based therapy in patients with type 2 diabetes and cardiovascular disease. Clinical Cardiology, 2019, 42, 1063-1070.	0.7	7
77	Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. Cardiovascular Diabetology, 2019, 18, 116.	2.7	14
78	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. American Heart Journal, 2019, 218, 57-65.	1.2	4
79	Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007124.	1.4	11
80	A New Personalized, Patient-Centric, and Cost-Conscious Guideline for Contemporary Cholesterol Management. JAMA - Journal of the American Medical Association, 2019, 321, 749.	3.8	1
81	Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. American Heart Journal, 2019, 213, 81-90.	1.2	10
82	Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. American Heart Journal, 2019, 214, 113-124.	1.2	17
83	Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. International Journal of Cardiology, 2019, 289, 58-62.	0.8	2
84	Thrombolysis in young adults with stroke. Neurology, 2019, 92, e2784-e2792.	1.5	20
85	Effect of a Quality Improvement Intervention on Adherence to Therapies for Patients With Acute Ischemic Stroke and Transient Ischemic Attack. JAMA Neurology, 2019, 76, 932.	4.5	23
86	Effect of a Quality of Care Improvement Initiative in Patients With Acute Coronary Syndrome in Resource-Constrained Hospitals in China. JAMA Cardiology, 2019, 4, 418.	3.0	31
87	Evaluation of Mortality Data From the Social Security Administration Death Master File for Clinical Research. JAMA Cardiology, 2019, 4, 375.	3.0	43
88	Trends in Readmissions and Length of Stay for Patients Hospitalized With Heart Failure in Canada and the United States. JAMA Cardiology, 2019, 4, 444.	3.0	75
89	Adolescent and Young Adult Recreational, Occupational, and Transportation Activity: Activity Recommendation and Weight Status Relationships. Journal of Adolescent Health, 2019, 65, 147-154.	1.2	7

Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the) Tj ETQq $0\ 0\ 0\ rgBT/Overlock\ 10\ Tf\ 50\ rgBT/Overlock\ 10\ rgBT/Overlock\$

#	Article	IF	Citations
91	Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. American Heart Journal, 2019, 212, 113-119.	1.2	70
92	Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation. Circulation: Cardiovascular Interventions, 2019, 12, e008160.	1.4	1
93	Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. American Heart Journal, 2019, 218, 100-109.	1.2	7
94	Machine Learning, Predictive Analytics, and Clinical Practice. JAMA - Journal of the American Medical Association, 2019, 322, 2283.	3.8	57
95	Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention. Circulation, 2019, 139, 458-472.	1.6	43
96	Ejection fraction, Bâ€type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure. Clinical Cardiology, 2019, 42, 277-284.	0.7	15
97	The association of pre- and posthospital medication adherence in myocardial infarction patients. American Heart Journal, 2019, 208, 74-80.	1.2	6
98	Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A) Tj ETQq0 0 0 0	gBT /Over 0.7	lock 10 Tf 50
99	Stroke prevention in atrial fibrillation: Closing the gap. American Heart Journal, 2019, 210, 29-38.	1.2	8
100	Quantifying Importance of Major Risk Factors for Coronary Heart Disease. Circulation, 2019, 139, 1603-1611.	1.6	115
101	An international cluster-randomized quality improvement trial to increase the adherence to evidence-based therapies for acute ischemic stroke and transient ischemic attack patients: Rationale and design of the BRIDGE STROKE Trial. American Heart Journal, 2019, 207, 49-57.	1.2	10
102	Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATEâ€ACS (Treatment With ADP Receptor) Tj ETQ	q0,0,0 rgB	T /Qverlock 1
103	Sustained sexâ€based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. Clinical Cardiology, 2018, 41, 758-768.	0.7	43
104	Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBITâ€AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. Journal of the American Heart Association, 2018, 7, .	1.6	6
105	Challenges in Interpreting the Lipid-Lowering Trials. JAMA - Journal of the American Medical Association, 2018, 319, 1549.	3.8	10
106	An Observational Study of the Association of Video-Versus Text-Based Informed Consent With Multicenter Trial Enrollment. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004675.	0.9	20
107	Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. JAMA - Journal of the American Medical Association, 2018, 319, 463.	3.8	180
108	Lipid Testing and Statin Dosing After Acute Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	1.6	22

#	Article	IF	CITATIONS
109	Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity and Metabolism, 2018, 20, 1427-1434.	2.2	23
110	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. Diabetes Care, 2018, 41, 596-603.	4.3	59
111	The association of Duration of participation in get with the guidelines-resuscitation with quality of Care for in-Hospital Cardiac Arrest. American Heart Journal, 2018, 204, 156-162.	1.2	23
112	Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry. American Heart Journal, 2018, 200, 118-124.	1.2	14
113	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity and Metabolism, 2018, 20, 1732-1739.	2.2	5
114	Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004249.	0.9	24
115	External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. Atherosclerosis, 2018, 272, 80-86.	0.4	24
116	Effect of Procedure and Coronary LesionÂCharacteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 626-634.	1.1	25
117	Inclusion of Functional Status MeasuresÂinÂthe Risk Adjustment of 30-Day Mortality After Transcatheter Aortic ValveÂReplacement. JACC: Cardiovascular Interventions, 2018, 11, 581-589.	1.1	49
118	Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. Europace, 2018, 20, 1-11.	0.7	80
119	How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?. American Heart Journal, 2018, 196, 163-169.	1.2	4
120	Access to routine care and risks for 30-day readmission in patients with cardiovascular disease. American Heart Journal, 2018, 196, 9-17.	1.2	21
121	Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs. American Heart Journal, 2018, 196, 170-177.	1.2	0
122	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. JAMA Cardiology, 2018, 3, 54.	3.0	77
123	Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. JAMA Cardiology, 2018, 3, 44.	3.0	346
124	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. Circulation, 2018, 137, 938-947.	1.6	17
125	Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences. JAMA Cardiology, 2018, 3, 1192.	3.0	48
126	Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. JAMA - Journal of the American Medical Association, 2018, 320, 2231.	3.8	72

#	Article	IF	CITATIONS
127	Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease. American Heart Journal, 2018, 206, 51-60.	1.2	7
128	Incidence, Management, and Associated Clinical Outcomes of New-Onset AtrialÂFibrillation Following TranscatheterÂAortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 1746-1756.	1.1	84
129	Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Non–STâ€Segment–Elevation Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	1.6	26
130	Statin Use and Adverse Effects Among Adults >75ÂYears of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. Journal of the American Heart Association, 2018, 7, .	1.6	49
131	Longâ€Term Mortality of Older Patients With Acute Myocardial Infarction Treated in US Clinical Practice. Journal of the American Heart Association, 2018, 7, .	1.6	58
132	Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2018, 46, 346-350.	1.0	10
133	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. Diabetes, Obesity and Metabolism, 2018, 20, 2379-2388.	2.2	29
134	Finding Means to Fulfill the Societal and Academic Imperative for Open Data Access and Sharing. JAMA Cardiology, 2018, 3, 793.	3.0	5
135	Adverse Change in Employment Status After Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004528.	0.9	27
136	Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Journal of Thrombosis and Thrombolysis, 2018, 46, 435-439.	1.0	9
137	Evaluating Health Technology Through Pragmatic Trials. JAMA - Journal of the American Medical Association, 2018, 320, 137.	3.8	19
138	International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Postâ€MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. Journal of the American Heart Association, 2018, 7, .	1.6	17
139	Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart, 2018, 104, 1850-1858.	1.2	23
140	Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2018, 11, e006322.	1.4	20
141	Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use. JAMA Cardiology, 2018, 3, 739.	3.0	94
142	Comparative Effectiveness, Safety, and Costs of Rivaroxaban and Warfarin Treatment Among Morbidly Obese Patients with Venous Thromboembolism. Blood, 2018, 132, 2537-2537.	0.6	2
143	Hospital Variation in Functional Recovery After Stroke. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	28
144	Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	82

#	Article	IF	Citations
145	Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care, 2017, 40, 494-501.	4.3	50
146	2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Annals of Thoracic Surgery, 2017, 103, 1021-1035.	0.7	38
147	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. International Journal of Cardiology, 2017, 230, 301-303.	0.8	9
148	Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients With Metabolic Syndrome. Annals of Thoracic Surgery, 2017, 104, 98-105.	0.7	7
149	Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	18
150	Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before Stroke. Circulation, 2017, 135, 1024-1035.	1.6	48
151	Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program― Circulation, 2017, 135, e22-e23.	1.6	2
152	Race and Sex Differences in Post–Myocardial Infarction Angina Frequency and Risk of 1-Year Unplanned Rehospitalization. Circulation, 2017, 135, 532-543.	1.6	37
153	Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Diabetes, Obesity and Metabolism, 2017, 19, 1587-1593.	2.2	24
154	New Treatment Options Fail to Close the Anticoagulation Gap in Atrial Fibrillation â—. Journal of the American College of Cardiology, 2017, 69, 2485-2487.	1.2	8
155	Depression Status Is Associated with Functional Decline Over 1-Year Following Acute Stroke. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 1393-1399.	0.7	20
156	Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). American Heart Journal, 2017, 189, 40-47.	1.2	53
157	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. Circulation, 2017, 136, 1193-1203.	1.6	47
158	Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. American Heart Journal, 2017, 189, 48-58.	1.2	29
159	When Less Is Not More â^—. Journal of the American College of Cardiology, 2017, 69, 2791-2793.	1.2	8
160	Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction. JAMA Cardiology, 2017, 2, 750.	3.0	50
161	An Initial Evaluation of the Impact of Pok \tilde{A} @mon GO on Physical Activity. Journal of the American Heart Association, 2017, 6, .	1.6	54
162	Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clinical Cardiology, 2017, 40, 746-751.	0.7	13

#	Article	IF	Citations
163	Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes. Stroke, 2017, 48, 1810-1817.	1.0	52
164	Outcomes of PCI in Relation to ProceduralÂCharacteristics and OperatorÂVolumes inÂthe United States. Journal of the American College of Cardiology, 2017, 69, 2913-2924.	1.2	104
165	Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non–Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the) Tj ETQq1 1 0. lournal of Cardiology, 2017, 119, 1590-1595.	784314 rg 0.7	BT ₃ Overlock
166	Corrections needed to 2016 ESC guideline and AHA scientific statement on heart failure. Lancet Diabetes and Endocrinology, the, 2017, 5, 325-326.	5.5	6
167	Assessment of Operator Variability in Risk-Standardized Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2017, 10, 672-682.	1.1	19
168	Outcomes of a multiâ€community hypertension implementation study: the American Heart Association's Check. Change. <i>Control</i>). program. Journal of Clinical Hypertension, 2017, 19, 479-487.	1.0	6
169	Site Principal Investigators in Multicenter Clinical Trials. Circulation, 2017, 135, 1185-1187.	1.6	10
170	Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2017, 317, 1057.	3.8	179
171	Predictors and Prognostic Implications ofÂlncident Heart Failure in Patients WithÂPrevalent Atrial Fibrillation. JACC: Heart Failure, 2017, 5, 44-52.	1.9	91
172	Quality of Evidence Underlying the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines on the Management of Atrial Fibrillation. JAMA Cardiology, 2017, 2, 319.	3.0	17
173	2016 Annual Report of TheÂSocietyÂofÂThoracic Surgeons/AmericanÂCollege of Cardiology Transcatheter Valve TherapyÂRegistry. Journal of the American College of Cardiology, 2017, 69, 1215-1230.	1.2	429
174	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal, 2017, 194, 132-140.	1.2	161
175	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care, 2017, 40, 1763-1770.	4.3	60
176	Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATEâ€ACS Study. Journal of the American Heart Association, 2017, 6, .	1.6	23
177	Unexplained Variation for Hospitals' Use of Inpatient Rehabilitation and Skilled Nursing Facilities After an Acute Ischemic Stroke. Stroke, 2017, 48, 2836-2842.	1.0	37
178	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. Hypertension, 2017, 70, 907-914.	1.3	12
179	Association of Neighborhood Demographics With Out-of-Hospital Cardiac Arrest Treatment and Outcomes. JAMA Cardiology, 2017, 2, 1110.	3.0	78
180	"Sticky―Issues for Adherence in Secondary Prevention. Journal of the American College of Cardiology, 2017, 70, 1555-1557.	1.2	3

#	Article	IF	CITATIONS
181	Glycemic control in patients undergoing coronary artery bypass graft surgery: Clinical features, predictors, and outcomes. Journal of Critical Care, 2017, 42, 328-333.	1.0	10
182	Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes) Tj ETQq0 0 0 rg	gB I. ¢Overlo	ock110 Tf 50
183	Transcatheter Versus Surgical AorticÂValveÂReplacement. Journal of the American College of Cardiology, 2017, 70, 439-450.	1.2	82
184	Socioeconomic, Psychosocial and Behavioral Characteristics of Patients Hospitalized With Cardiovascular Disease. American Journal of the Medical Sciences, 2017, 354, 565-572.	0.4	20
185	Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	29
186	The New 2017 ACC/AHA Guidelines "Up the Pressure―on Diagnosis and Treatment of Hypertension. JAMA - Journal of the American Medical Association, 2017, 318, 2083.	3.8	41
187	The Effect of Clinical Care Location onÂClinical Outcomes After PeripheralÂVascular Intervention in Medicare Beneficiaries. JACC: Cardiovascular Interventions, 2017, 10, 1161-1171.	1.1	26
188	Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Menâ€"Reply. JAMA Cardiology, 2017, 2, 108.	3.0	6
189	Cardioversion and subsequent quality of life and natural history of atrial fibrillation. American Heart Journal, 2017, 185, 59-66.	1.2	18
190	Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Non–ST-Segment Elevation Myocardial Infarction. JAMA Cardiology, 2017, 2, 36.	3.0	31
191	Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population. Circulation, 2017, 135, 128-139.	1.6	129
192	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation, 2017, 135, 323-333.	1.6	86
193	Sitagliptin and risk of fractures in type 2 diabetes: <scp>R</scp> esults from the <scp>TECOS</scp> trial. Diabetes, Obesity and Metabolism, 2017, 19, 78-86.	2.2	52
194	Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. Circulation, 2017, 135, 38-47.	1.6	16
195	Pancreatic Safety of Sitagliptin in the TECOS Study. Diabetes Care, 2017, 40, 164-170.	4.3	49
196	Management and outcomes of patients with atrial fibrillation and <i>a history of</i> cancer: the ORBIT-AF registry. European Heart Journal Quality of Care & Clinical Outcomes, 2017, 3, 192-197.	1.8	69
197	Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBITâ€AF (Outcomes Registry for Better Informed Treatment for Atrial) Tj ETQq1	1 0. 78431	4 4g BT /Over
198	Genetic Studies Help Clarify the Complexities of Lipid Biology and Treatment. JAMA - Journal of the American Medical Association, 2017, 318, 915.	3.8	5

#	Article	IF	CITATIONS
199	Identifying Nonclinical Factors Associated With 30-Day Readmission in Patients with Cardiovascular Disease: Protocol for an Observational Study. JMIR Research Protocols, 2017, 6, e118.	0.5	5
200	Abstract 21161: Use of an Open Access Multi-Sponsor Data Sharing Platform in Cardiology. Circulation, 2017, 136, .	1.6	0
201	Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. Thrombosis and Haemostasis, 2016, 116, S33-S40.	1.8	8
202	Assessment of Home-Time After Acute Ischemic Stroke in Medicare Beneficiaries. Stroke, 2016, 47, 836-842.	1.0	67
203	Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATEâ€ACS) Study, Journal of the American Heart Association, 2016, 5, .	1.6	14
204	Impact of Insurance Status on Outcomes and Use of Rehabilitation Services in Acute Ischemic Stroke: Findings From Get With The Guidelinesâ€Stroke. Journal of the American Heart Association, 2016, 5, .	1.6	46
205	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes. Journal of the American College of Cardiology, 2016, 68, 2597-2604.	1.2	401
206	Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e003070.	1.4	41
207	Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men. JAMA Cardiology, 2016, 1, 282.	3.0	182
208	Association of Get With The Guidelines-Stroke Program Participation and Clinical Outcomes for Medicare Beneficiaries With Ischemic Stroke. Stroke, 2016, 47, 1294-1302.	1.0	52
209	Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. American Heart Journal, 2016, 177, 33-41.	1.2	13
210	Gait Speed Predicts 30-Day Mortality After Transcatheter Aortic Valve Replacement. Circulation, 2016, 133, 1351-1359.	1.6	119
211	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 126.	3.0	196
212	Moving From Clinical Trials to Precision Medicine. JAMA - Journal of the American Medical Association, 2016, 315, 1713.	3.8	51
213	Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction With and Without Out-of-Hospital Cardiac Arrest. Journal of the American College of Cardiology, 2016, 67, 1981-1990.	1.2	39
214	The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation inÂBleeding Rates Following PercutaneousÂCoronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 771-779.	1.1	17
215	Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment. JAMA Cardiology, 2016, 1, 864.	3.0	29
216	How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2016, 181, 145-152.	1.2	13

#	Article	IF	Citations
217	Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation, 2016, 134, 1122-1124.	1.6	6
218	Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATEâ€ACS) Study. Journal of the American Heart Association, 2016, 5, .	1.6	9
219	Patient factors associated with quality of life in atrial fibrillation. American Heart Journal, 2016, 182, 135-143.	1.2	62
220	Outcomes 1 Year After Implantable Cardioverter–Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	25
221	Prior Antithrombotic Use Is Associated With Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke. Stroke, 2016, 47, 2066-2074.	1.0	12
222	Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure. Circulation, 2016, 134, 517-526.	1.6	90
223	Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age. Stroke, 2016, 47, 2347-2354.	1.0	27
224	Safety and clinical effectiveness of drugâ€eluting stents for saphenous vein graft intervention in older individuals: Results from the medicareâ€inked National Cardiovascular Data Registry [®] (2005–2009). Catheterization and Cardiovascular Interventions, 2016, 87, 43-49.	0.7	16
225	Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBITâ€AF Registry. Clinical Cardiology, 2016, 39, 119-125.	0.7	6
226	Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	127
227	Open Access Platforms for Sharing Clinical Trial Dataâ€"Reply. JAMA - Journal of the American Medical Association, 2016, 316, 666.	3.8	1
228	Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. JAMA - Journal of the American Medical Association, 2016, 316, 661.	3.8	33
229	Hospital Variation in Home-Time After Acute Ischemic Stroke. Stroke, 2016, 47, 2627-2633.	1.0	33
230	Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries. American Heart Journal, 2016, 179, 10-18.	1.2	14
231	Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. JAMA Cardiology, 2016, 1, 655.	3.0	19
232	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care, 2016, 39, 2304-2310.	4. 3	142
233	Selecting the Duration of AntiplateletÂTherapy Following Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2016, 68, 1865-1867.	1.2	0
234	Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence. JAMA - Journal of the American Medical Association, 2016, 316, 2041.	3.8	30

#	Article	IF	CITATIONS
235	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine, 2016, 375, 2423-2434.	13.9	1,265
236	Treatment, Outcomes, and Adherence to Medication Regimens Among Dual Medicare-Medicaid–Eligible Adults With Myocardial Infarction. JAMA Cardiology, 2016, 1, 787.	3.0	24
237	Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, $2016, 9, \ldots$	1.4	19
238	Variation in Hospital Risk–Adjusted Mortality Rates Following Transcatheter Aortic Valve Replacement in the United States. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 560-565.	0.9	43
239	Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG AD) Registry. Journal of the American Heart Association, 2016, 5, .	1.6	16
240	Trends in Robotic-Assisted Coronary Artery Bypass Grafts: A Study of The Society of Thoracic Surgeons Adult Cardiac Surgery Database, 2006 to 2012. Annals of Thoracic Surgery, 2016, 102, 140-146.	0.7	41
241	The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China. American Heart Journal, 2016, 175, 193-201.e3.	1.2	95
242	Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. American Journal of Medicine, 2016, 129, 592-599.e1.	0.6	49
243	Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes. Circulation, 2016, 133, 131-138.	1.6	70
244	Association of Hospital and Physician Characteristics and Care Processes With Racial Disparities in Procedural Outcomes Among Contemporary Patients Undergoing Coronary Artery Bypass Grafting Surgery. Circulation, 2016, 133, 124-130.	1.6	41
245	Use of Open Access Platforms for Clinical Trial Data. JAMA - Journal of the American Medical Association, 2016, 315, 1283.	3.8	57
246	Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. JAMA Cardiology, 2016, 1, 147.	3.0	80
247	Association of Body Mass Index WithÂCareÂand Outcomes in Patients WithÂAtrialÂFibrillation. JACC: Clinical Electrophysiology, 2016, 2, 355-363.	1.3	45
248	Has Public Reporting of Hospital Readmission Rates AffectedÂPatient Outcomes?. Journal of the American College of Cardiology, 2016, 67, 963-972.	1.2	46
249	Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. Circulation: Heart Failure, 2016, 9, e002630.	1.6	28
250	Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. American Heart Journal, 2016, 174, 29-36.	1,2	82
251	Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	1.6	10
252	Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	24

#	Article	IF	CITATIONS
253	Care Transitions After Acute Myocardial Infarction for Transferred-In Versus Direct-Arrival Patients. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 109-116.	0.9	9
254	Clinical Effectiveness of Hydralazine–Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. Circulation: Heart Failure, 2016, 9, e002444.	1.6	29
255	Sex and Race/Ethnicity–Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S36-44.	0.9	57
256	Endothelial Progenitor Cell Levels Predict Future Physical Function: An Exploratory Analysis From the VA Enhanced Fitness Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 362-369.	1.7	14
257	Association Between Hospital Process Composite Performance and Patient Outcomes After In-Hospital Cardiac Arrest Care. JAMA Cardiology, 2016, 1, 37.	3.0	56
258	Good Clinical Practice Guidance and Pragmatic Clinical Trials. Circulation, 2016, 133, 872-880.	1.6	79
259	Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction. Circulation, 2016, 133, 493-501.	1.6	26
260	Impact of Bleeding on Quality of Life in Patients on DAPT. Journal of the American College of Cardiology, 2016, 67, 59-65.	1.2	48
261	Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. American Heart Journal, 2015, 170, 706-714.	1.2	5
262	The Contemporary Use of Angiography and Revascularization Among Patients With Non– <scp>ST</scp> â€Segment Elevation Myocardial Infarction in the United States Compared With South Korea. Clinical Cardiology, 2015, 38, 708-714.	0.7	8
263	The Association of Transfer Rate From Hospitals Without Revascularization Capabilities and Mortality Risk for Older Non– <scp>ST</scp> â€Segment Elevation Myocardial Infarction Patients. Clinical Cardiology, 2015, 38, 733-739.	0.7	3
264	Use of Implantable Cardioverter-Defibrillators Among Medicare Patients—Reply. JAMA - Journal of the American Medical Association, 2015, 314, 1874.	3.8	4
265	Variation and Trends in the Documentation of National Institutes of Health Stroke Scale in GWTG-Stroke Hospitals. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S90-8.	0.9	29
266	Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction. Circulation, 2015, 132, 174-181.	1.6	45
267	Comparisons of Hospitalization Rates Among Younger Atrial Fibrillation Patients Receiving Different Antiarrhythmic Drugs. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 292-300.	0.9	10
268	Cumulative Incidence of Death and Rehospitalization Among the Elderly in the FirstÂYear after NSTEMI. American Journal of Medicine, 2015, 128, 582-590.	0.6	35
269	Three-Year Outcomes Associated With Embolic Protection in Saphenous Vein Graft Intervention. Circulation: Cardiovascular Interventions, 2015, 8, e001403.	1.4	47
270	Annual Outcomes With TranscatheterÂValve Therapy. Journal of the American College of Cardiology, 2015, 66, 2813-2823.	1.2	232

#	Article	IF	Citations
271	Smoke Signals. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	О
272	Early Medication Nonadherence After Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 347-356.	0.9	55
273	Response to Letters Regarding Article, "Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights From PREVENT IV― Circulation, 2015, 132, e29.	1.6	3
274	Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke. Journal of the American Heart Association, 2015, 4, .	1.6	12
275	Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverterâ€Defibrillator for Primary Prevention. Journal of the American Heart Association, 2015, 4, e002061.	1.6	14
276	Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan. American Heart Journal, 2015, 170, 1227-1233.	1.2	21
277	Outcomes of Patients With AcuteÂMyocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant andÂDualÂAntiplatelet Therapy. JACC: Cardiovascular Interventions, 2015, 8, 1880-1889.	1.1	87
278	Response to Letter Regarding Article, "Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease― Circulation, 2015, 132, e203.	1.6	2
279	Identification of Hospital Outliers in Bleeding Complications After Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 15-22.	0.9	13
280	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 499-508.	0.4	68
281	The Impact of Extreme-Risk Cases on Hospitals' Risk-Adjusted Percutaneous Coronary Intervention Mortality Ratings. JACC: Cardiovascular Interventions, 2015, 8, 10-16.	1.1	27
282	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. JACC: Heart Failure, 2015, 3, 159-167.	1.9	30
283	Translation of acute coronary syndrome therapies: From evidence to routine clinical practice. American Heart Journal, 2015, 169, 266-273.	1.2	14
284	Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. European Journal of Preventive Cardiology, 2015, 22, 1321-1327.	0.8	112
285	Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. Circulation, 2015, 131, 451-458.	1.6	283
286	Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. Circulation, 2015, 131, 488-494.	1.6	224
287	An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). American Heart lournal. 2015. 169. 472-478.e5.	1.2	140
288	Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 145-151.	2.1	14

#	Article	IF	CITATIONS
289	Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. Circulation, 2015, 132, 1404-1413.	1.6	43
290	The future of cardiovascular clinical research in North America and beyond—addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. American Heart Journal, 2015, 169, 743-750.	1.2	15
291	Rationale and design of a cluster-randomized multifaceted intervention trial to improve stroke care quality in China: The GOLDEN BRIDGE–Acute Ischemic Stroke. American Heart Journal, 2015, 169, 767-774.e2.	1.2	20
292	Participation in Cardiac Rehabilitation Programs Among Older Patients After Acute Myocardial Infarction. JAMA Internal Medicine, 2015, 175, 1700.	2.6	89
293	Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 421-427.	0.9	22
294	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. Circulation: Cardiovascular Interventions, 2015, 8, e001712.	1.4	16
295	Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 393-402.	0.9	173
296	Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2015, 313, 2433.	3.8	50
297	Trends in characteristics of cardiovascular clinical trials 2001-2012. American Heart Journal, 2015, 170, 263-272.e2.	1.2	26
298	Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 383-392.	0.9	52
299	Clinical Outcomes at 1 Year Following Transcatheter Aortic Valve Replacement. JAMA - Journal of the American Medical Association, 2015, 313, 1019.	3.8	412
300	Rational and design of a stepped-wedge cluster randomized trial evaluating quality improvement initiative for reducing cardiovascular events among patients with acute coronary syndromes in resource-constrained hospitals in China. American Heart Journal, 2015, 169, 349-355.	1.2	24
301	Using Age- and Sex-Specific Risk Thresholds to Guide Statin Therapy. Journal of the American College of Cardiology, 2015, 65, 1633-1639.	1.2	58
302	Trends in Settings for Peripheral Vascular Intervention and the Effect of Changes inÂthe Outpatient Prospective PaymentÂSystem. Journal of the American College of Cardiology, 2015, 65, 920-927.	1.2	138
303	Association Between Divorce and Risks for Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 244-251.	0.9	46
304	<i>JAMA</i> Cardiovascular Disease Theme Issue. JAMA - Journal of the American Medical Association, 2015, 313, 1718.	3.8	0
305	Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. European Journal of Preventive Cardiology, 2015, 22, 317-325.	0.8	94
306	Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non–ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry). American Journal of Cardiology, 2015, 115, 1655-1660.	0.7	7

#	Article	IF	Citations
307	The Impact of High-Risk Cases on Hospitals' Risk-Adjusted Coronary Artery Bypass Grafting Mortality Rankings. Annals of Thoracic Surgery, 2015, 99, 856-862.	0.7	19
308	Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. American Heart Journal, 2015, 170, 141-148.e1.	1.2	211
309	The Lasker Awards—Recognizing and Valuing Investments in Cardiovascular Research. JAMA - Journal of the American Medical Association, 2015, 314, 1121.	3.8	0
310	Quality of Care and Ischemic Stroke Risk After Hospitalization for Transient Ischemic Attack. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S117-S124.	0.9	15
311	Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 567-575.	0.9	9
312	Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2015, 314, 1973.	3.8	53
313	Impact of Patient Characteristics on Hospital-Level Outcomes Assessment in Congenital Heart Surgery. Annals of Thoracic Surgery, 2015, 100, 1071-1077.	0.7	33
314	Utility of Socioeconomic Status in Predicting 30-Day Outcomes After Heart Failure Hospitalization. Circulation: Heart Failure, 2015, 8, 473-480.	1.6	55
315	Effectiveness of cardiac rehabilitation among older patients after acute myocardial infarction. American Heart Journal, 2015, 170, 855-864.	1.2	67
316	Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBITâ€AF). Journal of the American Heart Association, 2015, 4, e002031.	1.6	41
317	Quality-Cost Relationship in Congenital Heart Surgery. Annals of Thoracic Surgery, 2015, 100, 1416-1421.	0.7	36
318	Antiarrhythmic Drug Use in Patients <65ÂYears With Atrial Fibrillation and Without Structural Heart Disease. American Journal of Cardiology, 2015, 115, 316-322.	0.7	23
319	Temporal Trends for Secondary Prevention Measures Among Patients Hospitalized with Coronary Artery Disease. American Journal of Medicine, 2015, 128, 426.e1-426.e9.	0.6	31
320	Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke. American Heart Journal, 2015, 169, 39-44.e2.	1.2	51
321	Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV Trial. American Heart Journal, 2015, 169, 175-184.	1.2	23
322	Abstract 12266: Treatment and Outcomes of Dual Medicare/Medicaid Eligible Older Adults With Myocardial Infarction. Circulation, 2015, 132, .	1.6	0
323	Check It, Change It. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 828-834.	0.9	30
324	Open Access to Clinical Trials Data. JAMA - Journal of the American Medical Association, 2014, 312, 1002.	3.8	43

#	Article	IF	CITATIONS
325	The Association of Transcatheter Aortic Valve Replacement Availability and Hospital Aortic ValveÂReplacement Volume and Mortality in theÂUnited States. Annals of Thoracic Surgery, 2014, 98, 2016-2022.	0.7	74
326	Proportion of US Adults Potentially Affected by the 2014 Hypertension Guideline. JAMA - Journal of the American Medical Association, 2014, 311, 1424.	3.8	95
327	Rates of Cardiopulmonary Resuscitation Training in the United States. JAMA Internal Medicine, 2014, 174, 194.	2.6	131
328	In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2014, 7, 585-593.	1.4	49
329	Differences in Short-Term Versus Long-Term Outcomes of Older Black Versus White Patients With Myocardial Infarction. Circulation, 2014, 130, 659-667.	1.6	30
330	The Learning Curve for Transradial Percutaneous Coronary Intervention Among Operators in the United States. Circulation, 2014, 129, 2277-2286.	1.6	156
331	Revascularization in Stable Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2014, 312, 2028.	3.8	0
332	Vein Graft Preservation Solutions, Patency, and Outcomes After Coronary Artery Bypass Graft Surgery. JAMA Surgery, 2014, 149, 798.	2.2	74
333	Progress Against Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2014, 312, 1979.	3.8	2
334	Examination of the Treatment Selection Process in a Multicenter Observational Study. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 764-769.	0.9	0
335	Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. JAMA - Journal of the American Medical Association, 2014, 311, 2209.	3.8	35
336	Racial/Ethnic Differences in Process of Care and Outcomes Among Patients Hospitalized With Intracerebral Hemorrhage. Stroke, 2014, 45, 3243-3250.	1.0	35
337	Strategies to Overcome Medication Nonadherence—Reply. JAMA - Journal of the American Medical Association, 2014, 311, 1693.	3.8	1
338	The Impact of Differential Case Ascertainment in Clinical Registry Versus Administrative Data on Assessment of Resource Utilization in Pediatric Heart Surgery. World Journal for Pediatric & Samp; Congenital Heart Surgery, 2014, 5, 398-405.	0.3	22
339	Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: Insights from the ClinicalTrials.gov registry. American Heart Journal, 2014, 168, 213-219.e1.	1,2	73
340	Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non–ST-segment elevation myocardial infarction. American Heart Journal, 2014, 167, 267-273.e1.	1.2	13
341	Adherence and Persistence in the Use of Warfarin After Hospital Discharge Among Patients With Heart Failure and Atrial Fibrillation. Journal of Cardiac Failure, 2014, 20, 23-30.	0.7	20
342	Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation. Circulation, 2014, 129, 2005-2012.	1.6	73

#	Article	IF	CITATIONS
343	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2014, 167, 735-742.e2.	1.2	120
344	Normal Coronary Rates for Elective Angiography in the Veterans Affairs Healthcare System. Journal of the American College of Cardiology, 2014, 63, 417-426.	1.2	67
345	Recommendations for Treating Hypertension. JAMA - Journal of the American Medical Association, 2014, 311, 474.	3.8	31
346	Development of a Clinical Registry-Based 30-Day Readmission Measure for Coronary Artery Bypass Grafting Surgery. Circulation, 2014, 130, 399-409.	1.6	65
347	Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 793-799.	2.1	45
348	Excess Costs Associated With Complications and Prolonged Length of Stay After Congenital Heart Surgery. Annals of Thoracic Surgery, 2014, 98, 1660-1666.	0.7	79
349	Persistence of Evidence-Based Medication Use After Discharge from Academic Versus Nonacademic Hospitals Among Patients With Non–ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2014, 114, 1479-1484.	0.7	14
350	Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. Europace, 2014, 16, 1284-1290.	0.7	9
351	Comparison of Safety of Sotalol Versus Amiodarone inÂPatients With Atrial Fibrillation and Coronary Artery Disease. American Journal of Cardiology, 2014, 114, 716-722.	0.7	9
352	Chronic Kidney Disease and Bleeding Complications After Intravenous Thrombolytic Therapy for Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 929-935.	0.9	35
353	Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery. Circulation, 2014, 130, 1445-1451.	1.6	181
354	Do patients treated at academic hospitals have better longitudinal outcomes after admission for non–ST-elevation myocardial infarction?. American Heart Journal, 2014, 167, 762-769.	1.2	16
355	The impact of a measurement and feedback intervention on blood pressure control in ambulatory cardiology practice. American Heart Journal, 2014, 167, 466-471.	1.2	4
356	Early Post-Discharge Bleeding and Antiplatelet Therapy Discontinuation Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 63, 1700-1702.	1.2	10
357	Trends in the Use and Outcomes of Ventricular AssistÂDevices Among MedicareÂBeneficiaries, 2006ÂThrough 2011. Journal of the American College of Cardiology, 2014, 63, 1395-1404.	1.2	56
358	Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry. American Heart Journal, 2014, 168, 160-167.	1.2	62
359	Developing a Risk Model for In-Hospital Adverse Events Following Implantable Cardioverter-Defibrillator Implantation. Journal of the American College of Cardiology, 2014, 63, 788-796.	1.2	37
360	Central venous pressure after coronary artery bypass surgery: Does it predict postoperative mortality or renal failure?. Journal of Critical Care, 2014, 29, 1006-1010.	1.0	57

#	Article	IF	Citations
361	Abstract 15680: Sinus Node Dysfunction in Associated With Higher Symptom Burden and Increased Risk of Progression to Permanent Atrial Fibrillation: Results From ORBIT-AF Registry. Circulation, 2014, 130, .	1.6	0
362	Associations Between Use of the Hospitalist Model and Quality of Care and Outcomes of Older Patients Hospitalized for Heart Failure. JACC: Heart Failure, 2013, 1, 445-453.	1.9	30
363	Successful linking of the Society of Thoracic Surgeons Database to Social Security data to examine the accuracy of Society of Thoracic Surgeons mortality data. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 976-983.	0.4	29
364	Validated, Electronic Health Record Deployable Prediction Models for Assessing Patient Risk of 30-Day Rehospitalization and Mortality in Older Heart Failure Patients. JACC: Heart Failure, 2013, 1, 245-251.	1.9	95
365	Ingredients of Successful Interventions to Improve Medication Adherence. JAMA - Journal of the American Medical Association, 2013, 310, 2611.	3.8	111
366	Temporal Trends and Geographic Variation of Lower-Extremity Amputation in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2012, 60, 2230-2236.	1.2	158
367	Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): Results from a National Data Validation Audit. American Heart Journal, 2012, 163, 392-398.e1.	1.2	145
368	Early Anticoagulation of Bioprosthetic Aortic Valves in Older Patients. Journal of the American College of Cardiology, 2012, 60, 971-977.	1.2	122
369	Public Reporting of Cardiac Surgery Performance: Part 1â€"History, Rationale, Consequences. Annals of Thoracic Surgery, 2011, 92, S2-S11.	0.7	141
370	Public Reporting of Cardiac Surgery Performance: Part 2â€"Implementation. Annals of Thoracic Surgery, 2011, 92, S12-S23.	0.7	93
371	Racial-Ethnic Disparities in Stroke Care: The American Experience. Stroke, 2011, 42, 2091-2116.	1.0	397
372	Successful Linking of The Society of Thoracic Surgeons Adult Cardiac Surgery Database to Centers for Medicare and Medicaid Services Medicare Data. Annals of Thoracic Surgery, 2010, 90, 1150-1157.	0.7	148
373	Relationship Between Early Physician Follow-up and 30-Day Readmission Among Medicare Beneficiaries Hospitalized for Heart Failure. JAMA - Journal of the American Medical Association, 2010, 303, 1716.	3.8	852
374	ACCF/AHA 2010 Position Statement on Composite Measures for Healthcare Performance Assessment. Journal of the American College of Cardiology, 2010, 55, 1755-1766.	1.2	57
375	Vision and Creation of the American Heart Association Pharmaceutical Roundtable Outcomes Research Centers. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 663-670.	0.9	3
376	A Call to ACTION (Acute Coronary Treatment and Intervention Outcomes Network). Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 491-499.	0.9	187
377	Eliminating Racial and Ethnic Disparities in Cardiac Care. New England Journal of Medicine, 2009, 360, 1172-1174.	13.9	55
378	Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack. Circulation, 2009, 119, 107-115.	1.6	505

#	Article	IF	CITATIONS
379	Implementing Critical Pathways and a Multidisciplinary Team Approach to Cardiovascular Disease Management. American Journal of Cardiology, 2008, 102, 47G-56G.	0.7	28
380	Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. American Heart Journal, 2008, 156, 1045-1055.	1.2	216
381	Association of Evidence-Based Care Processes and Outcomes Among Patients With Acute Coronary Syndromes. Journal of Cardiovascular Nursing, 2008, 23, 50-55.	0.6	17
382	Socioeconomic disparities in outcomes after acute myocardial infarction. American Heart Journal, 2007, 153, 313-319.	1.2	119
383	Insurance Coverage and Care of Patients with Non–ST-Segment Elevation Acute Coronary Syndromes. Annals of Internal Medicine, 2007, 147, 212.	2.0	0
384	Guideline Implementation Research: Exploring the Gap between Evidence and Practice in the CRUSADE Quality Improvement Initiative. Academic Emergency Medicine, 2007, 14, 949-954.	0.8	30
385	The burden of angina pectoris and its complications complications. Clinical Cardiology, 2007, 30, 110-115.	0.7	11
386	Association Between Hospital Process Performance and Outcomes Among Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2006, 295, 1912.	3.8	588
387	Prognostic/Clinical Prediction Models: Using Observational Data to Estimate Prognosis: An Example Using a Coronary Artery Disease Registry. , 2005, , 287-314.		0
388	Prediction of operative mortality after valve replacement surgery. Journal of the American College of Cardiology, 2001, 37, 885-892.	1.2	380
389	Using observational data to estimate prognosis: an example using a coronary artery disease registry. Statistics in Medicine, 2001, 20, 2505-2532.	0.8	22
390	Evaluating the Potential ???Economic Attractiveness??? of New Therapies in Patients with Non-ST Elevation Acute Coronary Syndrome. Pharmacoeconomics, 2000, 17, 263-272.	1.7	12
391	Health Economics of Acute Coronary Syndromes. Journal of Thrombosis and Thrombolysis, 1998, 5, S161-S168.	1.0	4
392	Comparing risk-adjustment methods for provider profiling. , 1998, 16, 2645-2664.		186
393	Prediction of severe coronary artery disease by combined rest and exercise radionuclide angiocardiography and tomographic perfusion imaging with technetium 99m-labeled sestamibi: A comparison with clinical and electrocardiographic data1. Journal of Nuclear Cardiology, 1997, 4, 189-194.	1.4	20
394	Relationship Between Diabetes Mellitus and Long-term Survival After Coronary Bypass and Angioplasty. Circulation, 1997, 96, 2551-2556.	1.6	225
395	Impact of an interactive video on decision making of patients with ischemic heart disease. Journal of General Internal Medicine, 1996, 11, 373-376.	1.3	86
396	Operator-Specific Outcomes. Circulation, 1996, 93, 403-406.	1.6	27

#	Article	IF	CITATIONS
397	The HEART Pathway: Just A Heart Score Permutation or the Future of Clinical Decision Rules?. Academic Emergency Medicine, 0, , .	0.8	0